JB
Therapeutic Areas
Talphera Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Niyad™ (nafamostat mesylate) | Regional anticoagulation for Continuous Renal Replacement Therapy (CRRT)/Intermittent Hemodialysis (IHD) | Phase 3 |
| LTX-608™ (nafamostat) | Various inflammatory/coagulopathic indications (e.g., DIC, COVID-19, ARDS, Acute Pancreatitis) | Preclinical/Phase 3* |
| Fedsyra™ (ephedrine PFS) | Treatment of hypotension during general anesthesia | Phase 3 |
| PFS-02 (phenylephrine PFS) | Treatment of hypotension due to vasodilation | Phase 3 |
Leadership Team at Talphera
VJ
Vincent J. Angotti
Chief Executive Officer
RA
Raffi Asadorian
Chief Financial Officer
BD
Badri Dasu
Chief Engineering Officer
SA
Shakil Aslam, MD
Chief Medical Officer
AA
Adrian Adams
Chairman of the Board of Directors
MB
Marina Bozilenko
Board Member
SJ
Stephen J. Hoffman, PhD, MD
Board Member
A'
Abhinav 'Abi' Jain
Board Member
JT
Joseph Todisco
Board Member
MW
Mark Wan
Board Member